Webb, Tonya J
MetadataShow full item record
AbstractNatural killer T (NKT) cells are a unique subset of lymphocytes that recognize lipid antigens in the context of the non-classical class I MHC molecule, CD1d, and serve as a link between the innate and adaptive immune system through their expeditious release of cytokines. Whereas NKT have well-established roles in mitigating a number of human diseases, herein, we focus on their role in cancer. NKT cells have been shown to directly and indirectly mediate anti-tumor immunity and manipulating their effector functions can have therapeutic significances in treatment of cancer. In this review, we highlight several therapeutic strategies that have been used to harness the effector functions of NKT cells to target different types of solid tumors. We also discuss several barriers to the successful utilization of NKT cells and summarize effective strategies being developed to harness the unique strengths of this potent population of T cells. Collectively, studies investigating the therapeutic potential of NKT cells serve not only to advance our understanding of this powerful immune cell subset, but also pave the way for future treatments focused on the modulation of NKT cell responses to enhance cancer immunotherapy.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15957
- Immunotherapeutic strategies targeting natural killer T cell responses in cancer.
- Authors: Shissler SC, Bollino DR, Tiper IV, Bates JP, Derakhshandeh R, Webb TJ
- Issue date: 2016 Aug
- Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells.
- Authors: East JE, Kennedy AJ, Webb TJ
- Issue date: 2014 Jan
- Natural Killer T Cells in Cancer Immunotherapy.
- Authors: Nair S, Dhodapkar MV
- Issue date: 2017
- Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
- Authors: Favreau M, Vanderkerken K, Elewaut D, Venken K, Menu E
- Issue date: 2016 Apr 26
- Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant <i>Staphylococcus aureus</i> Infection.
- Authors: Genardi S, Visvabharathy L, Cao L, Morgun E, Cui Y, Qi C, Chen YH, Gapin L, Berdyshev E, Wang CR
- Issue date: 2020